comparemela.com

Latest Breaking News On - Robotics daily - Page 1 : comparemela.com

Bellevue Group AG Decreases Holdings in PROCEPT BioRobotics Co (NASDAQ:PRCT)

Bellevue Group AG trimmed its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) by 0.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 885,346 shares of the company’s stock after selling 2,950 shares during the period. Bellevue Group AG’s holdings […]

Q2 2024 Earnings Estimate for PROCEPT BioRobotics Co Issued By Leerink Partnrs (NASDAQ:PRCT)

PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) – Equities researchers at Leerink Partnrs lifted their Q2 2024 earnings per share estimates for shares of PROCEPT BioRobotics in a report released on Tuesday, May 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of ($0.55) per share for the quarter, up […]

Leerink Partnrs Brokers Raise Earnings Estimates for PROCEPT BioRobotics Co (NASDAQ:PRCT)

PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) – Equities researchers at Leerink Partnrs raised their Q2 2024 earnings estimates for PROCEPT BioRobotics in a report issued on Tuesday, May 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($0.55) per share for the quarter, up from their previous estimate of ($0.56). […]

Brokerages Set PROCEPT BioRobotics Co (NASDAQ:PRCT) Target Price at $61 20

PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have updated their coverage on the stock in […]

PROCEPT BioRobotics Co (NASDAQ:PRCT) Given Consensus Rating of Buy by Analysts

Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.